| Autor: |
Tran Thi Nhu Mai, Bruce May, Ung Trong Thuan, Nguyen Mai Khoi, Nguyen Thi Thuy Trang, Dinh Van Long, Doan Chinh Chung, Tran The Vinh, Khong Hiep, Nguyen Thi Thanh Truc, Hua Hoang Quoc Huy, Nguyen Viet Anh, Ha Tan Phat, Phan Dang Luu, Nguyen Truong An, Bui Thi Ngoc, Tu Tieu My, Nguyen Thi Theo, Le Thi Thuy Hang, Dong Thi Lan, Huynh Trong Hieu, Ho Phien Huong, Le Nguyen Thanh Thao, Truong Cong Thao, Pham Hoang Phi, Y Luong Cong, Nie Lim, Cao Minh Ngoc, Nguyen Duy Khanh, Trinh Thanh Hung, Do Minh Si |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.07.20.453162 |
| Popis: |
The Coronavirus disease-2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has become a dire global health concern. The development of vaccines with high immunogenicity and safety is crucial for control of the global COVID-19 pandemic and prevention of further illness and fatalities. Here, we report development of SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the S protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG, as well neutralizing antibody in three animal models including Balb/C mice, Syrian hamsters, and non-human primate (Macaca leonina). In addition, the viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. No adverse effects were induced by Nanocovax in swiss mice (Musmusculus var. Albino), Rats (Rattus norvegicus), and New Zealand rabbits. These pre-clinical results indicated that Nanocovax is safe and effective. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
